Abstract Library

#4532 Gender differences in patients with medullary thyroid cancer (MTC): A single-centre experience

Introduction: Medullary thyroid cancer (MTC) accounts for 3-5% of thyroid tumours. It can be sporadic or associated with genetic syndrome. The role of gender in the MTC isn’t clarified.

Conference:

Presenting Author:

Authors: Cannavale G, Minotta R, Liccardi A, Benevento E, Di Iasi G,

Keywords: MTC, gender difference, gender medicine,

#4503 Duodenopancreatic neuroendocrine tumour in MEN1: Gender difference and survival rates

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is the most common inherited syndrome associated with NET development and metastatic duodenal-pancreatic (DP) NET is the main cause of death.

Conference:

Presenting Author: Liccardi A

Authors: Liccardi A, Roberto M, Cannavale G, Benevento E, Di Iasi G,

Keywords: Multiple endocrine neoplasia type 1, neuroendocrine tumour, gender difference, survival,

#4448 Statins and somatostatin analogues in gastroenteropancreatic neuroendocrine tumours (GEP-NET): Impact on overall survival

Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NET) are rare neoplasia with unclear risk factor influencing their development and survival. Statins appear to enhance antiproliferative effect of some chemotherapies in other cancers, but their effect in GEP-NET treated with somatostatin analogues (SSA) are largely unknown.

Conference:

Presenting Author: Benevento E

Authors: Benevento E, Liccardi A, Minotta R, Cannavale G, Di Iasi G,

Keywords: statins, neuroendocrine tumour, gastroenteropancreatic, overall survival, somatostatin analogue,

#4408 Metabolic syndrome (MetS) and metastatic disease in patients with sporadic small intestine neuroendocrine tumour (SiNET)

Introduction: Small intestine neuroendocrine tumours (SiNETs) are rare neoplasms in which the identification of new risk factors is essential. Metabolic syndrome (MetS) is a cluster of risk factors that lead to increased mortality, especially by cardiovascular (CV) causes. MetS diagnosis is obtained with International Diabetes Federation (IDF) 2005 criteria.

Conference:

Presenting Author: Minotta R

Authors: Minotta R, Liccardi A, Cannavale G, Benevento E, Di Iasi G,

Keywords: small intestine neuroendocrine tumour, metabolic syndrome, metastatic disease, survival, progression, metastasis,

#4358 Patients with neuroendocrine tumour after surgical treatment and therapy with somatostatin analogues: Comparison of body mass index (BMI)

Introduction: Neuroendocrine tumours (NET) are heterogeneous neoplasms, commonly arising in the gastroenteropancreatic tract (GEP-NET) or bronchopulmonary (L-NET). Surgery is the first line treatment, when possible, while somatostatin analogues (SSA) are the main medical therapy. However, the impact of these therapies on anthropometric indices has not been fully explored.

Conference:

Presenting Author:

Authors: Di Iasi G, Benevento E, Cannavale G, Di Nola M, Liccardi A,

Keywords: BMI, NET, SSA, SURGERY, WEIGHT LOSS, GEP-NET, LUNG NET, WAIST CIRCUMFERENCE, HIP CIRCUMFERENCE,